These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26071225)

  • 1. Negative PET: no guarantee of good prognosis in Hodgkin's lymphoma.
    Adams HJ; Kwee TC
    Ann Hematol; 2015 Sep; 94(9):1609-10. PubMed ID: 26071225
    [No Abstract]   [Full Text] [Related]  

  • 2. Negative PET: good prognosis for Hodgkin's lymphoma.
    Bagcchi S
    Lancet Oncol; 2015 Jun; 16(6):e265. PubMed ID: 25936985
    [No Abstract]   [Full Text] [Related]  

  • 3. Hodgkin's lymphoma: evolving concepts with implications for practice.
    Meyer RM; Ambinder RF; Stroobants S
    Hematology Am Soc Hematol Educ Program; 2004; ():184-202. PubMed ID: 15561683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
    Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S; Montoto S
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
    Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).
    Rigacci L; Puccini B; Zinzani PL; Biggi A; Castagnoli A; Merli F; Balzarotti M; Stelitano C; Spina M; Vitolo U; Stefoni V; Levis A; Gotti M; Rosaria S; Maria SP; Bosi A; Gallamini A
    Am J Hematol; 2015 Jun; 90(6):499-503. PubMed ID: 25720750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Juweid ME
    J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
    [No Abstract]   [Full Text] [Related]  

  • 11. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET scanning and prognosis in Hodgkin's lymphoma.
    Brepoels L; Stroobants S
    Curr Opin Oncol; 2008 Sep; 20(5):509-16. PubMed ID: 19106652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusual discrepancy between CT and PET/CT in the initial staging of Hodgkin's lymphoma.
    Michelis FV; Exarhos DN; Tzannou IA; Karmiris T; Nikiforakis E
    Acta Oncol; 2011 Apr; 50(3):474-6. PubMed ID: 20715895
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma.
    Gallamini A
    Haematologica; 2010 Jul; 95(7):1046-8. PubMed ID: 20595100
    [No Abstract]   [Full Text] [Related]  

  • 20. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease.
    Poulou LS; Karianakis G; Ziakas PD
    Eur J Radiol; 2009 Jun; 70(3):499-506. PubMed ID: 18342471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.